Guilford Pharmaceuticals Inc. - GLFD- Profile

Guilford Pharmaceuticals Incorporated. The Group's principal activity is the research, development and marketing of proprietary pharmaceutical products for the hospital and neurology markets. It markets approved pharmaceutical products, conducts clinical research to expand the labeled indications for its marketed products and conducts clinical development on pharmaceutical product candidates. GLIADEL(R) Wafer is a proprietary cancer chemotherapy product approved in the United States for the treatment of malignant glioma, a form of primary brain cancer and recurrent glioblastoma multiforme, a rapidly fatal form of malignant brain cancer. AGGRASTAT(R) Injection is indicated for the treatment of acute coronary syndrome. AQUAVAN(R) Injection is a novel sedative/hypnotic that is an IV formulation of a water-soluble prodrug of a widely-used anesthetic, propofol. DOPASCAN(R) Injection is a product candidate to diagnose and monitor the degree of Parkinson's disease as represented by dopamine transporter binding. Develops and markets products that enable a controlled delivery of drugs, using biodegradable polymers